CoChat

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

Open access
Shen, Li, Sundstedt, Anette, Ciesielski, Michael, Miles, Kiersten Marie, Celander, Mona, Adelaiye, Remi, Orillion, Ashley, Ciamporcero, Eric, Ramakrishnan, Swathi, Ellis, Leigh, Fenstermaker, Robert, Abrams, Scott I., Eriksson, Helena, Leanderson, Tomas, Olsson, Anders, Pili, Roberto · 2015 · Cancer Immunology Research
Cited by 92

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

A major barrier for cancer immunotherapy is the presence of suppressive cell populations in patients with cancer, such as myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM), which contribute to the immunosuppressive microenvironment that promotes tumor growth and metastasis. Tasquinimod is a novel antitumor agent that is currently at an advanced stage of clinical development for treatment of castration-resistant prostate cancer. A target of tasquinimod is the inflammatory protein S100A9, which has been demonstrated to affect the accumulation and function of tumor-suppressive myeloid cells. Here, we report that tasquinimod provided a significant enhancement to the antitumor effects of two different immunotherapeutics in mouse models of cancer: a tumor vaccine (SurVaxM) for prostate cancer and a tumor-targeted superantigen (TTS) for melanoma. In the combination strategies, tasquinimod inhibited distinct MDSC populations and TAMs of the M2-polarized phenotype (CD206+). CD11b+ myeloid cells isolated from tumors of treated mice expressed lower levels of arginase-1 and higher levels of inducible nitric oxide synthase (iNOS), and were less immunosuppressive ex vivo, which translated into a significantly reduced tumor-promoting capacity in vivo when these cells were coinjected with tumor cells. Tumor-specific CD8+ T cells were increased markedly in the circulation and in tumors. Furthermore, T-cell effector functions, including cell-mediated cytotoxicity and IFNγ production, were potentiated. Taken together, these data suggest that pharmacologic targeting of suppressive myeloid cells by tasquinimod induces therapeutic benefit and provide the rationale for clinical testing of tasquinimod in combination with cancer immunotherapies. Cancer Immunol Res; 3(2); 136–48. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-14-0036

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 92

Metadata

Authors
Shen, L., Sundstedt, A., Ciesielski, M., Miles, K. M., Celander, M., Adelaiye, R., Orillion, A., Ciamporcero, E., Ramakrishnan, S., Ellis, L., Fenstermaker, R., Abrams, S. I., Eriksson, H., Leanderson, T., Olsson, A., & Pili, R.
Venue
Cancer Immunology Research
Published
2015-02-01
Volume
3
Issue
2
Pages
136-148
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2149008396
Cited by
92
References
13
FWCI
4.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0036
The paper
Shen, L., Sundstedt, A., Ciesielski, M., Miles, K. M., Celander, M., Adelaiye, R., Orillion, A., Ciamporcero, E., Ramakrishnan, S., Ellis, L., Fenstermaker, R., Abrams, S. I., Eriksson, H., Leanderson, T., Olsson, A., & Pili, R. (2015). Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.